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Themolecular identification ofimmunogenicdeterminants onhumancancer cells
provides a basis for understanding the immune response to cancer. Two classes of
antigens on human melanoma cells have received particular attention as targets for
immune recognition: (a) unique antigens expressed only by autologous melanoma
cells (1), and (b) differentiation antigens expressed normally by cells of the melano-
cytelineage(2, 3). Differentiation antigens ofmelanocytes havebeen defined bytheir
relationship to other well-defined phenotypic traits expressed during melanocyte
differentiation (2, 3), themostdistinctivebeingthe synthesis ofthe pigmentmelanin
within melanosomes.
Clinical observations have suggested, albeit indirectly, that an immune response
directed against differentiation antigens expressed by normal pigment cells might
influence the course of metastatic melanoma (4, 5). In this regard, melanosomal
antigens potentiallycould be recognized bythe immunesystem. This hasbeen demon-
strated directly by immunoprecipitation of a gp75 antigen from autologous mela-
noma cellsbyserum IgGantibodies ofapatient with metastatic melanoma (6). The
gp75 antigen is amelanosomalpolypeptide that is the most abundant glycoprotein
synthesized by pigmented melanocytes and melanomas (7; Vijayasaradhi, S., and
Houghton, A. N., unpublished observations). Epidermal melanocytes, benign pig-
mented lesions, and primary and metastatic melanomas express gp75, but other
cell typesdonot(8). Thus, gp75 is a prominent tissue-specific glycoprotein in mela-
nocytic cells and is potentially autoimmunogenic. In this study, we set out to iden-
tify the gp75 antigen, and report that it is the human counterpart of a product of
agene atthe mouse b locus, aregion thatdetermines thetype ofmelanin synthesized.
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Materials and Methods
BriefDefinitive Report
Tissue Culture.
￿
The melanoma cell line SK-MEL-19 cell line was grown in MEM plus
1% nonessential amino acids and penicillin and streptomycin, except that SerumPlus 10%
(vol/vol) (Hazelton Research Products Inc., Lenexa, KS) was substituted for FCS.
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Isolation andPurification ofgp75.
￿
Postnuclear membrane fraction from melanoma cell line
SK-MEL-19 was isolated. High salt (3 M KCl) insoluble, detergent (0.5% deoxycholate) soluble
protein fraction was collected and applied to a Mono Q(Pharmacia LKB Biotechnology Inc.,
Piscataway, NJ) anion-exchange column . Bound proteins were eluted with a linear gradient
of0-1 .0 M NaCl. Fractions were assayed for gp75 by a competitive inhibition assay that mea-
sured inhibition of binding of mouse mAb TA99 (300 ng/ml) (9) to SK-MEL-19 cells fixed
in methanol/acetone (1 :1 vol/vol) by enzyme immunoassay (3). Fractions containing gp75
were pooled, applied to a Con A-Sepharose column, and bound proteins were eluted with
0.25 M a-D-methylmannopyranoside. Fractions containing gp75 were pooled and applied
to a mAb TA99 Affi-Gel 10,affinity column. Bound gp75 was eluted from the column with
0.1 M glycine-HCI, pH 3.1.
Immunoprecipitation, Gel Electrophoresis, and Peptide Mapping.
￿
Iodination of Con A-Seph-
arose-bound protein fraction ofSK-MEL-19 by chloramine T method and immunoprecipi-
tation with mAb TA99 and AU serum was done as described (6). Proteins were analyzed
by one- and two-dimensional SDS-PAGE (10, 11). For endoglycosidase H (Endo H) diges-
tion, the immunoprecipitates were suspended in 0.4% SDS, heated at 100°C for 5 min, and
digested with 1 mU of Endo H (Genzyme Corp., Boston, MA) in 100 mM citrate buffer,
pH 5.5, for 16 h at 37°C. Peptide mapping of immunoprecipitated gp75 was performed by
limited proteolysis with Staphylococcus aureus V8 protease (V8 protease) (Boehringer Mann-
heim Biochemicals, Indianapolis, IN) in SDS-PAGE according to Cleveland et al. (12).
Peptide Sequencing. Peptide sequencing was performed at the Harvard University
Microchemistry Facility. Purified gp75 (12 kg) electroblotted onto nitrocellulose was digested
with V8 protease (1 :20 wt/wt) according to Aebersold et al. (13), and resulting peptides were
separated on a Brownlee RP-300 C8 column. Peaks from V8 protease digests were pooled.
Reduced and alkylated peptide fractions were digested with trypsin (1 :25 wt/wt) overnight
at 37°C. Fractions were sequenced on an ABI 477A protein sequencer (Applied Biosystems
Inc., Foster City, CA).
Cloning andSequencing of,gp75 cDNA.
￿
A cDNA library was constructed from a melanoma
cell line SK-MEL-19. Oligonucleotide probe was used to isolate a gp75 cDNA clone according
to methods previously described (14). The sequence of the oligonucleotide probe was: 5'
CTCGAAGGTGAAGCCCAGGTTGTCGGGGGCGGTCACGAACATCTC3'.A2 .0-kb
cDNA clone, designated GP75-1, was sequenced (Stratagene Cloning Systems, LaJolla, CA).
The nucleotide sequence of GP75-1 has been deposited with EMBL data bank under the
accession number X51455.
Results and Discussion
Both mouse mAb TA99 and serum from melanoma patient AU immunoprecipi-
tate a 75-kD antigen, and mAb TA99 preclears the gp75 antigen precipitated by
AU serum (9). Since mAb TA99 was used to purify gp75 from the melanoma cell
line SK-MEL-19, it was important to confirm that mAb TA99 detected only the gp75
antigen recognized by AU serum. In previous studies, we had shown that mAb TA99
does not react with human tyrosinase, a 75-80-kD glycoprotein also expressed in
pigmented melanocytes (14). However, from these experiments, we could not rule
out the possibility that mAb TA99 crossreacts with other polypeptides expressed by
SK-MEL-19.
Proteins immunoprecipitated by mAb TA99 and AU serum antibody were ana-
lyzed by one- and two-dimensional SDS-PAGE and by peptide maps using limited
proteolysis with S. aureus V8 protease. Proteins precipitated with both mAb TA99
and AU serum antibodies had identical molecular masses (75 kD), isoelectric points
(5 .5-5.9) (data not shown), and peptide composition (Fig. 1), confirming that TA99
and AU serum recognized the same gp75 molecule.
The gp75 antigen was purified as described in the Materials and Methods. Affinity-VIJAYASARADHI ET AL .
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FIGURE 1.
￿
Immunoprecipitationand
peptide composition analysis of pro-
teins recognized bymAbTA99 andAU
serum . (A) One-dimensional SDS-
PAGE of immunoprecipitates from
125I-labeled lysates of SK-MEL-19 by
mAb TA99 (lane 1), normal human
serum (lane 2), andtwo serum speci-
mens from patient AU drawn 22 mo
apart (lanes 3and 4). (B)Bands corre-
sponding to gp75 or to gp75 treated
with EndoH(partially deglycosylated)
were excised from SDS-polyacrylamide
gel and the peptide composition was
analyzed by limited digestion with
S . aureus V8 protease on SDS-PAGE .
(-)gp75 ; (+) gp75 partially deglyco-
sylated with EndoH . Autoradiographic
exposure was 2 d forTA99 and 5 d for
AU peptides .
purified gp75 was used for peptide sequencing . The amino acid sequences of three
internal peptides were obtained by proteolytic cleavage of purified gp75 with V8
protease andtrypsin . The sequences ofthe three peptides are shownin Fig . 2 . There
was 90% identity withaminoacid sequences deducedfrom themousecDNA clone,
pMT4, isolated by Shibahara et al . (at amino acid positions 247-260, 333-349, and
428-441 ofpMT4) (15) . Oligonucleotide probes were derivedfrom peptide sequences
of p75 and used to screen acDNA library constructed from the human melanoma
cell line SK-MEL-19 . A cDNA clone (2.0 kb) was isolated from acDNA library of
SK-MEL-19 . Partial nucleotide sequence ofthecDNA clone (GP75-1) showed 88.6%
identity with pMT4 (between nucleotides 649 and 1395 within the open reading
frame) . The derived amino acid sequence of GP75-1 showed 93 .6% identity with
the derived amino acid sequence of pMT4 between amino acid residues 193 and
441 . There was 55.3% identity between thecDNA sequences of gp75 and human
tyrosinase (14) (between nucleotides 615 and 1359 of tyrosinase; data not shown) .
The close homology between human gp75 and the deducedproduct ofthemouse
pMT4 gene sheds some light on the possible structure and function of gp75 . The
pMT4 clonewas isolated from mouse melanocytic cells (15) . Originally pMT4 cDNA
was thought to code for mouse tyrosinase, which maps to the mouse c (albino) locus .
However, further studies showed that pMT4 is distinct from tyrosinase (14, 16) . Like-
wise, the sequence of gp75 is distinct from the sequence of human tyrosinase, al-
though there is limited identity (43.1%) between gp75 and the derived amino acid
sequence ofhuman tyrosinase (between amino acid residues 187 and 434) (14) . The
1 . AsnThr-Val-Glu-GIyTyr-SerAsp-Pro-Thr-Gly-LysTyr-Asp-Pro-AIaVaI
2 . Met-PheValThr-Ala-Pro-Asp-Asn-Leu-GIyTyr-Thr-Tyr-Glu
3. Asn-Phe-Asp-Ser-Thr-Leu-Ileu-Ser-Pro-Asn-Ser-Val-Phe-Ser
FIGURE 2 .
￿
Amino acid sequence of three peptides derived from gp75 . (Boldface) Amino acid
residues that differ from residues predicted from the mouse cDNA pMT4 .1378
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function of gp75 andthe pMT4 product is suggestedby the finding that pMT4 maps
to the b (brown) locus in the mouse (17), a region that regulates coat color (18). The
homology between gp75 and the deduced amino acid sequence of pMT4 permits
the formal identification of the human homologue of the mouse brown locus gene
product. Basedon itsmelanosomal localization andstructural similarity to tyrosinase,
the gp75 molecule mayregulate melanin synthesis, and determine the type of melanin
synthesized.
It has been perceived that melanosomal determinants and other intracellular an-
tigens arenot potential targets forimmunotherapyof melanoma. However, recently
it has become evident that intracellular proteins can be processed and presented
as peptides to CTL by APCs (19). This finding opens up the theoretical possibility
that T cell responses against melanoma couldbe directed against moleculesexpressed
within the tumor cell. Alternatively, melanosomal components, which are normally
transportedoutside the melanocyte during maturation, couldaccumulate in the ex-
tracellular space around tumor cells, or local tissue necrosis could lead to release
and deposition of intracellular products. In support of the accessibility of gp75, ra-
diolabeled TA99 mAbspecifically localizes to humanmelanoma xenografts in nu/nu
mice (20), indicating the availability of the antigen to antibody within tumor sites.
IgG antibodies in the melanoma patient AU recognized determinants on gp75
that were shared by melanoma cells and normal melanocytes (6). With the isolation
ofcDNA clones that code for gp75, it should be possible to study strategies for active
immunization against gp75 . There are at least tworequirements for effective induc-
tion of CTL responses to gp75 : (a) immune tolerance to gp75 must be broken, and
(b) gp75 peptides must be processed and effectively presented by major histocom-
patibility antigens on melanoma cells. Alternatively, it is possible that differentia-
tion antigens of melanocytes couldcarry unique determinants. Genes encoding prod-
ucts expressed by normal melanocytes could be mutated or rearranged during
malignant transformation, generating novel epitopes for recognition by CTL and
antibodies. In this regard, the best characterized unique antigen on human mela-
noma cells is adeterminanton melanotransferrin, a95-97-kD glycoprotein expressed
on cultured melanocytes and melanoma cells (1, 21). In support of this possibility,
genetic alterations have been detected at high frequency and widely throughout the
genome of human melanoma cells (22, 23).
Summary
The gp75 antigen is an abundant intracellular glycoprotein expressed in melano-
somes of human pigmented melanocytes and melanomas. IgG antibodies in sera
of apatient with metastatic melanoma have been shown to immunoprecipitate gp75,
suggesting that immunological tolerance against gp75 can be broken. The mouse
mAb TA99, which specifically recognizes gp75, was used to isolate and purify the
antigen. Amino acid sequences of three internal peptides were determined from the
purified gp75 polypeptide. cDNA clones were isolated by screeningwith oligonucle-
otides based on these peptide sequences. The gp75 peptides and cDNA had -90%
identity with, respectively, the derived amino acid and nucleotide sequences of a
mouse gene that maps to the b (brown) locus. The brown locus determines coat color
in the mouse, suggesting that gp75 regulates or influences the type of melanin syn-
thesized.VIJAYASARADHI ET AL.
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